Ikena Oncology, Inc. - Common Stock (IKNA)

IKNA stock results show that Ikena Oncology beat analyst estimates for earnings per share the second quarter of 2024.

Ikena Oncology halts its IK-930 program after reviewing clinical data and resources, focusing on the novel MEK-RAF molecular glue, IK-595.

It's time to start the day with a breakdown of the biggest pre-market stock movers traders are going to want to watch on Wednesday morning!

IKNA stock results show that Ikena Oncology beat analyst estimates for earnings per share the first quarter of 2024.

Ikena Oncology optimizes resources for targeted oncology programs IK-930 & IK-595. Clinical updates expected H2 2024. Workforce reduced by 35%. Financially secure with $175M cash. Strategic focus on key developments in 2024.

Shares of Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) surged in pre-market trading after the company announced its foray into the Middle Ea

U.S. stocks traded lower toward the end of trading, with the Dow Jones falling over 200 points on Thursday. The Dow traded down 0.71% to 33,871.77 while the NASDAQ fell 0.87% to 13,531.36. The S&P 500 also fell, dropping, 0.80% to 4,347.67.

Ikena Oncology Inc (NASDAQ: IKNA) shared initial data from twenty-six patients treated in the ongoing dose escalation portion of the 

Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results.

U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 50 points on Thursday. The Dow traded up 0.01% to 34,114.64 while the NASDAQ rose 0.35% to 13,697.53. The S&P 500 also rose, gaining, 0.16% to 4,389.61.

Ikena Oncology Inc (NASDAQ: IKNA) is garnering attention with its oncology-focused pipeline, and the company's recent developments have raised optimism in the medical community. 

We're starting off the day with a look at all of the biggest pre-market stock movers worth keeping an eye on for Tuesday!